Ramucirumab Cyramza®
The SHIKARI® Ramucirumab portfolio provides a quantitative free-drug assay and a qualitative anti-ramucirumab antibody assay for human serum or plasma.
Why Ramucirumab is relevant to biological-drug monitoring research
Ramucirumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Ramucirumab is a fully human IgG1 monoclonal antibody that binds VEGFR2 and inhibits ligand-induced receptor activation and downstream angiogenic signalling. Source ↗
Approved Indications
EMA-authorised uses include defined settings in gastric/gastro-oesophageal-junction adenocarcinoma, metastatic colorectal cancer, non-small cell lung cancer and hepatocellular carcinoma. EMA source ↗
Exposure and Persistence
Current regulator data show a long half-life and attainment of steady state after repeated dosing; original regulatory-development data also provide a regimen-specific trough reference:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two verified Ramucirumab research assays
Ligand-binding ELISA for quantitative analysis of free ramucirumab in human serum or plasma.
Qualitative ELISA for positive or negative assessment of anti-ramucirumab antibodies in human serum or plasma according to assay-specific cut-off interpretation.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-RAM | RAM-FD-CYR | Quantitative | Free ramucirumab | Human serum / plasma | 10 µL | 70 min | LOD 5; LOQ 20 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATRAM | RAM-QLS-CYR | Qualitative | Anti-ramucirumab antibodies | Human serum / plasma | 20 µL | 140 min | Positive; negative | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Ramucirumab Literature and Product-Use Records
Planning a Ramucirumab research study?
Matrix Biotek can help identify the appropriate Ramucirumab assay and prepare regional quotation and delivery information.